Article ; Online: Are Pax proteins potential therapeutic targets in kidney disease and cancer?
2018 Volume 94, Issue 2, Page(s) 259–267
Abstract: Pax genes encode developmental regulators that are expressed in a variety of tissues and control critical events in morphogenesis. In the kidney, Pax2 and Pax8 are expressed in embryonic development and in specific renal diseases associated with aberrant ...
Abstract | Pax genes encode developmental regulators that are expressed in a variety of tissues and control critical events in morphogenesis. In the kidney, Pax2 and Pax8 are expressed in embryonic development and in specific renal diseases associated with aberrant epithelial cell proliferation. Prior genetic and cell biological studies suggest that reducing the activity of Pax proteins in renal cancer or in polycystic kidney disease can slow the progression of these conditions. The Pax proteins may be critical for providing tissue and locus specificity to recruit epigenetic modifiers that control gene expression and chromatin structure. Although they are nuclear, targeting Pax proteins to inhibit function may be feasible with small molecules. Such inhibition of Pax protein function may provide novel therapies for subsets of renal disorders that are tissue- and cell type-specific and avoid systemic effects on non-Pax-expressing cells and tissues. Given the paucity of effective treatments for renal cancer and cystic disease, the Pax family of proteins represents new pharmaceutical targets that merit exploration and further development. |
---|---|
MeSH term(s) | Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Disease Progression ; Epigenesis, Genetic/drug effects ; Epithelial Cells/drug effects ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Gene Expression Regulation, Developmental/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Kidney/cytology ; Kidney/growth & development ; Kidney/metabolism ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/genetics ; Kidney Neoplasms/pathology ; Molecular Targeted Therapy/methods ; PAX2 Transcription Factor/antagonists & inhibitors ; PAX2 Transcription Factor/genetics ; PAX2 Transcription Factor/metabolism ; PAX8 Transcription Factor/antagonists & inhibitors ; PAX8 Transcription Factor/genetics ; PAX8 Transcription Factor/metabolism ; Polycystic Kidney Diseases/drug therapy ; Polycystic Kidney Diseases/genetics ; Polycystic Kidney Diseases/pathology ; Protein Domains/drug effects ; Urothelium/cytology ; Urothelium/drug effects ; Urothelium/metabolism ; Urothelium/pathology |
Chemical Substances | Antineoplastic Agents ; PAX2 Transcription Factor ; PAX2 protein, human ; PAX8 Transcription Factor ; PAX8 protein, human |
Language | English |
Publishing date | 2018-04-21 |
Publishing country | United States |
Document type | Journal Article ; Research Support, N.I.H., Extramural ; Review |
ZDB-ID | 120573-0 |
ISSN | 1523-1755 ; 0085-2538 |
ISSN (online) | 1523-1755 |
ISSN | 0085-2538 |
DOI | 10.1016/j.kint.2018.01.025 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 797: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.